期刊文献+

达英-35预防环磷酰胺对大鼠卵巢功能损伤的实验研究 被引量:5

Experimental study of the prevention of Diane-35 cyclophosphamide-induced ovarian damage in rat model
下载PDF
导出
摘要 目的:研究口服避孕药达英-35在雌性大鼠中减轻环磷酰胺(CTX)诱导的性腺毒性的效果。方法:随机将75只雌性Wistar大鼠分为5组:空白对照组、CTX组、达英-35组、联合治疗Ⅰ组和联合治疗Ⅱ组。用放射免疫法测定各组雌二醇(E2)和卵泡刺激素(FSH)水平,并于停药当天、第15天、30天,处死各组1/3的大鼠,比较卵巢重量、卵泡数量变化。结果:停药第30天,CTX组大鼠E2为(21.88±2.10)pg/ml,明显低于两个联合治疗组,FSH为(7.05±0.18)mIU/ml,明显高于两个联合治疗组,差异均有统计学意义(P<0.05);CTX组卵巢重量和卵泡总数分别为(32.40±5.55)mg和308±32个,明显低于两个联合治疗组,差异有统计学意义(P<0.05);联合治疗Ⅰ、Ⅱ组的E2、FSH、卵巢重量、卵泡数量分别比较,差异无统计学意义(P>0.05)。结论:达英-35降低了CTX对大鼠卵巢功能的损伤,对卵巢功能的保护和恢复起到了一定的作用。 Objective:To study the effect of oral contraceptives(OC) Diane-35 against cyclophosphamide(CTX)induced gonadotoxicity in the female rats.Methods:75 female Wistar rats were divided into five groups:blank control group,CTX group,Diane-35 group,combination groupⅠ,combination groupⅡ.E2,FSH were measured by RIA,and one-third of rats in each group were killed respectively on the stop day,15 days,30 days to compare the weight of ovary and the number of follicles.Results:On stop 30 days,E2 of CTX group was (21.88±2.10)pg/ml,lower than that of combination groups(P0.05),FSH was(7.05±0.18)mIU/ml,higher than that of combination groups(P0.05),ovary weight and total follicle number of CTX group were (32.40±5.55)mg and 308±32,obviously lower than those of combination groups(P0.05).No significant differences were found between the two combination groups in E2,FSH,ovary weight and follicle number(P0.05).Conclusion:Diane-35 may decrease CTX-induced ovarian damage in rat and plays a potential role in protecting and restoring ovarian function.
作者 王敏 何援利
出处 《现代妇产科进展》 CSCD 北大核心 2010年第7期498-501,共4页 Progress in Obstetrics and Gynecology
关键词 卵巢功能试验 环磷酰胺 达英-35 大鼠 Wistar 疾病模型 动物 Ovarian function tests Cyclophosphamide Diane-35 Rats Wistar Disease models animal
  • 相关文献

参考文献11

  • 1Marehesoni D, Driul L, Fruscalzo A, et al. Premature ovarian failure in patients affected by oncohematological disease [J]. Minerva Ginecol,2005 ,57 :545-550.
  • 2Familiari G, Caffiati A, Nottola SA, et al. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease[ J]. Hum Reprod, 1993,8 : 2080-2087.
  • 3Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease [ J ]. Blood, 1981,58 : 849-851.
  • 4Manger K, Wildt L, Kalden JR,et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-study [ J ]. Autoimmun Rev, 2006,5 : 269-272.
  • 5Molina JR, Barton DL, Loprinzi CL. Chemotherapy induced ovarian failure : manifestations and management [ J ]. Drug Saf,2005 ,28 :401-416.
  • 6袁光文,沈铿,杨佳欣.促性腺激素释放激素激动剂对化疗损伤卵巢功能保护作用的实验研究[J].中华妇产科杂志,2005,40(10):666-669. 被引量:34
  • 7Raz A,Fiseh B, Okon E, et al. Possible direct cytotoxicity effects of cyclophosphamide on cultured human follicles: an electron microscopy study[ J ]. J Assist Reprod Genet, 2002,19 : 500 -506.
  • 8Desmeules P, Devine PJ. Characterizing the ovotoxieity of cyclophosphamide metabolites on cultured mouse ovaries [J].Toxicol Sci ,2006,90:500-509.
  • 9Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors[ J]. Oncoloqist,2006,11:96-110.
  • 10Medard ML, Ostrowska L. Combined oral contraception and the risk of reproductive organs cancer in women [ J]. Ginekol Pol,2007,78:643-641.

二级参考文献6

  • 1Ataya K, Moghissi K. Chemotherapy induced premature ovarian failure: mechanisms and prevention. Steroids, 1989, 54: 607-626.
  • 2Ataya KM, McKanna JA, Weintraub AM, et al. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res, 1985,45: 3651-3656.
  • 3Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinizing hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadatoxicity in female rats. Br J Cancer, 1990,61: 861-865.
  • 4Montz FJ, Wolff AJ, Gambone JC. Gonadal protection and fecundity rates in cyclophosphamide-treated rats. Cancer Res, 1991,51: 2124-2126.
  • 5Seifer DB, Gardiner AC, Ferreira KA, et al. Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization. Fertil Steril, 1996,66:593-598.
  • 6周毛婴.不孕症妇女卵巢储备监测及意义[J].国外医学(计划生育分册),2001,20(2):94-97. 被引量:13

共引文献33

同被引文献85

  • 1杨岫岩,朱旬,梁柳琴,詹钟平,叶玉津.环磷酰胺治疗系统性红斑狼疮导致卵巢功能衰竭的相关因素分析[J].中华医学杂志,2005,85(14):960-962. 被引量:26
  • 2石一复,谢幸,赵承洛,吕卫国,万小云.放线菌素D、环磷酰胺、氨甲喋呤序贯化疗对卵巢功能的影响[J].中华医学杂志,1996,76(1):45-48. 被引量:7
  • 3彭萍,杨冬梓,莫亚勤,郑澄宇,罗璐,张清学.1-磷酸-神经鞘氨醇预防化疗大鼠卵巢功能损害的实验研究[J].中山大学学报(医学科学版),2007,28(1):15-18. 被引量:12
  • 4徐叔云,卞如濂.药理实验方法学[M].北京:人民卫生出版社,2006:1758-1762.
  • 5Hong H, Yen HY, Brockmeyer A, et al. Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer [J]. Cancer Res, 2010,70( 1 ) :221-228.
  • 6Lutchman SK,Davies M,Chatterjee R. Fertility in female cancer survivors: pathophysiology,preservation and the role of ovarian reserve testing[J]. Hum Reprod Update,2005,11( 1 ) :69-89.
  • 7高慧,夏天,韩冰,杨涓.中药补肾调冲方治疗卵巢早衰的临床研究[J].辽宁中医杂志,2007,34(11):1557-1560. 被引量:34
  • 8Skillern A,Rajkovic A. Recent developments in identifying genetic determinants of premature ovarian failure[J].Sex Dev,2008,(4/5):228-243.
  • 9Mattle V,Behringer K,Engert A. Female fertility after cytotoxic therapy-protection of ovarian function during chemotherapy of malignant and non-malignant disease[J].European Journal of Haematology Supplementum,2005,(66):77-82.
  • 10Demeestere I,Simon P,Buxant F. Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation:case report[J].Human Reproduction,2006,(08):2010-2014.doi:10.1093/humrep/del092.

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部